Cancer mouse models: Past, present and future

Seminars in Cell and Developmental Biology

Volumn 27, Issue , 2014, Pages 54-60

  Khaled, Walid T ^b   Liu, Pentao ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer models; Cas9; Gene targeting; PDX; Transgenics

Indexed keywords

CANCER GROWTH; CANCER MODEL; CANCER RESEARCH; CARCINOGENESIS; GENE TARGETING; GENETIC SCREENING; MOUSE MODEL; NONHUMAN; REVIEW; TRANSGENIC MOUSE; TUMOR GENE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; MEDICAL RESEARCH; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; GENES, NEOPLASM; HUMANS; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL;

EID: 84901289279     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.04.003     Document Type: Review

References (94)

1. Guenet J.L. The mouse genome. Genome Res 2005, 15:1729-1740.
2. Emes R.D., Goodstadt L., Winter E.E., Ponting C.P. Comparison of the genomes of human and mouse lays the foundation of genome zoology. Hum Mol Genet 2003, 12:701-709.
3. Cree I.A., Glaysher S., Harvey A.L. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 2010, 10:375-379.
4. Ertel A., Verghese A., Byers S.W., Ochs M., Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer 2006, 5:55.
5. Gillet J.P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A 2011, 108:18708-18713.
6. Stein W.D., Litman T., Fojo T., Bates S.E. A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 2004, 64:2805-2816.
7. Siolas D., Hannon G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013, 73:5315-5319.
8. Zhang X.C., Zhang J., Li M., Huang X.S., Yang X.N., Zhong W.Z., et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med 2013, 11:168.
9. Mattie M., Christensen A., Chang M.S., Yeh W., Said S., Shostak Y., et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia (New York, NY) 2013, 15:1138-1150.
10. Topp M.D., Hartley L., Cook M., Heong V., Boehm E., McShane L., et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014.
11. Scott C.L., Becker M.A., Haluska P., Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 2013, 3:295.
12. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520.
13. Fichtner I., Slisow W., Gill J., Becker M., Elbe B., Hillebrand T., et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004, 40:298-307.
14. Malaney P., Nicosia S.V., Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett 2014, 344:1-12.
15. Houghton P.J., Morton C.L., Tucker C., Payne D., Favours E., Cole C., et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood Cancer 2007, 49:928-940.
16. Neale G., Su X., Morton C.L., Phelps D., Gorlick R., Lock R.B., et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572-4583.
17. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Therapeut 2011, 10:1311-1316.
18. Brinster R.L., Chen H.Y., Messing A., van Dyke T., Levine A.J., Palmiter R.D. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984, 37:367-379.
19. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
20. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12:954-961.
21. Schonig K., Schwenk F., Rajewsky K., Bujard H. Stringent doxycycline dependent control of CRE recombinase in vivo. Nucleic Acids Res 2002, 30:e134.
22. Smith M.C., Brown W.R., McEwan A.R., Rowley P.A. Site-specific recombination by phiC31 integrase and other large serine recombinases. Biochem Soc Trans 2010, 38:388-394.
23. Kuehn M.R., Bradley A., Robertson E.J., Evans M.J. A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 1987, 326:295-298.
24. Robertson E., Bradley A., Kuehn M., Evans M. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 1986, 323:445-448.
25. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
26. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., Weinberg R.A. Effects of an Rb mutation in the mouse. Nature 1992, 359:295-300.
27. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., et al. Negative regulation of neural stem/progenitor cell proliferation by the PTEN tumor suppressor gene in vivo. Science (New York, NY) 2001, 294:2186-2189.
28. McCarthy A., Savage K., Gabriel A., Naceur C., Reis-Filho J.S., Ashworth A. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 2007, 211:389-398.
29. Sherr C.J. Principles of tumor suppression. Cell 2004, 116:235-246.
30. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
31. Cheon D.J., Orsulic S. Mouse models of cancer. Ann Rev Pathol 2011, 6:95-119.
32. Gowen L.C., Johnson B.L., Latour A.M., Sulik K.K., Koller B.H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996, 12:191-194.
33. Sharan S.K., Morimatsu M., Albrecht U., Lim D.S., Regel E., Dinh C., et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997, 386:804-810.
34. Evers B., Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006, 25:5885-5897.
35. Molyneux G., Geyer F.C., Magnay F-A., McCarthy A., Kendrick H., Natrajan R., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
36. Zambrowicz B.P., Imamoto A., Fiering S., Herzenberg L.A., Kerr W.G., Soriano P. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A 1997, 94:3789-3794.
37. Rodenhuis S. ras and human tumors. Semin Cancer Biol 1992, 3:241-247.
38. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001, 15:3243-3248.
39. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
40. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003, 17:3112-3126.
41. Sansom O.J., Meniel V., Wilkins J.A., Cole A.M., Oien K.A., Marsh V., et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 2006, 103:14122-14127.
42. Madisen L., Zwingman T.A., Sunkin S.M., Oh S.W., Zariwala H.A., Gu H., et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 2010, 13:133-140.
43. Safran M., Kim W.Y., Kung A.L., Horner J.W., DePinho R.A., Kaelin W.G. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging 2003, 2:297-302.
44. Metzger D., Clifford J., Chiba H., Chambon P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci U S A 1995, 92:6991-6995.
45. Zhang Y., Riesterer C., Ayrall A.M., Sablitzky F., Littlewood T.D., Reth M. Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res 1996, 24:543-548.
46. Feil S., Valtcheva N., Feil R. Inducible Cre mice. Methods Mol Biol 2009, 530:343-363.
47. St-Onge L., Furth P.A., Gruss P. Temporal control of the Cre recombinase in transgenic mice by a tetracycline responsive promoter. Nucleic Acids Res 1996, 24:3875-3877.
48. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
49. Loonstra A., Vooijs M., Beverloo H.B., Allak B.A., van Drunen E., Kanaar R., et al. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A 2001, 98:9209-9214.
50. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
51. Goldman J.M., Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
52. Zheng B., Sage M., Cai W.W., Thompson D.M., Tavsanli B.C., Cheah Y.C., et al. Engineering a mouse balancer chromosome. Nat Genet 1999, 22:375-378.
53. Yu Y., Bradley A. Engineering chromosomal rearrangements in mice. Nat Rev Genet 2001, 2:780-790.
54. Buchholz F., Refaeli Y., Trumpp A., Bishop J.M. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep 2000, 1:133-139.
55. Carlson D.F., Fahrenkrug S.C., Hackett P.B. Targeting DNA with fingers and TALENs. Mol Therapy Nucleic Acids 2012, 1:e3.
56. Mali P., Esvelt K.M., Church G.M. Cas9 as a versatile tool for engineering biology. Nat Methods 2013, 10:957-963.
57. Bhaya D., Davison M., Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 2011, 45:273-297.
58. Wiedenheft B., Sternberg S.H., Doudna J.A. RNA-guided genetic silencing systems in bacteria and archaea. Nature 2012, 482:331-338.
59. Horvath P., Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science (New York, NY) 2010, 327:167-170.
60. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., et al. RNA-guided human genome engineering via Cas9. Science (New York, NY) 2013, 339:823-826.
61. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., et al. Multiplex genome engineering using CRISPR/Cas systems. Science (New York, NY) 2013, 339:819-823.
62. Pattanayak V., Lin S., Guilinger J.P., Ma E., Doudna J.A., Liu D.R. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013, 31:839-843.
63. Cradick T.J., Fine E.J., Antico C.J., Bao G. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 2013, 41:9584-9592.
64. Ran F.A., Hsu P.D., Lin C.Y., Gootenberg J.S., Konermann S., Trevino A.E., et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154:1380-1389.
65. Wang H., Yang H., Shivalila C.S., Dawlaty M.M., Cheng A.W., Zhang F., et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013, 153:910-918.
66. TCGA Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
67. TCGA Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
68. Akagi K., Suzuki T., Stephens R.M., Jenkins N.A., Copeland N.G. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004, 32:D523-D527.
69. Copeland N.G., Jenkins N.A. Harnessing transposons for cancer gene discovery. Nat Rev Cancer 2010, 10:696-706.
70. Collier L.S., Carlson C.M., Ravimohan S., Dupuy A.J., Largaespada D.A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005, 436:272-276.
71. Dupuy A.J., Akagi K., Largaespada D.A., Copeland N.G., Jenkins N.A. Mammalian mutagenesis using a highly mobile somatic sleeping beauty transposon system. Nature 2005, 436:221-226.
72. Rad R., Rad L., Wang W., Cadinanos J., Vassiliou G., Rice S., et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science (New York, NY) 2010, 330:1104-1107.
73. Dupuy A.J., Rogers L.M., Kim J., Nannapaneni K., Starr T.K., Liu P., et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009, 69:8150-8156.
74. Starr T.K., Allaei R., Silverstein K.A., Staggs R.A., Sarver A.L., Bergemann T.L., et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (New York, NY) 2009, 323:1747-1750.
75. Keng V.W., Villanueva A., Chiang D.Y., Dupuy A.J., Ryan B.J., Matise I., et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009, 27:264-274.
76. Vassiliou G.S., Cooper J.L., Rad R., Li J., Rice S., Uren A., et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011, 43:470-475.
77. Perez-Mancera P.A., Rust A.G., van der Weyden L., Kristiansen G., Li A., Sarver A.L., et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012, 486:266-270.
78. Kokubu C., Takeda J. When half is better than the whole: advances in haploid embryonic stem cell technology. Cell Stem Cell 2014, 14:265-267.
79. Guo G., Wang W., Bradley A. Mismatch repair genes identified using genetic screens in Blm-deficient embryonic stem cells. Nature 2004, 429:891-895.
80. Shalem O., Sanjana N.E., Hartenian E., Shi X., Scott D.A., Mikkelsen T.S., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (New York, NY) 2014, 343:84-87.
81. Wang T., Wei J.J., Sabatini D.M., Lander E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science (New York, NY) 2014, 343:80-84.
82. Koike-Yusa H., Li Y., Tan E-P., Velasco-Herrera M.D.C., Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 2013, 32:267-273.
83. Macdonald L.E., Karow M., Stevens S., Auerbach W., Poueymirou W.T., Yasenchak J., et al. Precise and in situ genetic humanization of 6Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014, 111(14):5147-5152.
84. Murphy A.J., Macdonald L.E., Stevens S., Karow M., Dore A.T., Pobursky K., et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014, 111(14):5153-5158.
85. Lee E.C., Liang Q., Ali H., Bayliss L., Beasley A., Bloomfield-Gerdes T., et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol 2014, 32:356-363.
86. Regeneron. http://www.regeneron.com/oncology.
87. Dick J.E., Lapidot T., Pflumio F. Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis. Immunol Rev 1991, 124:25-43.
88. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004, 101:4966-4971.
89. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
90. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001, 29:418-425.
91. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
92. Derksen P.W., Liu X., Saridin F., van der Gulden H., Zevenhoven J., Evers B., et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449.
93. Reilly K.M., Loisel D.A., Bronson R.T., McLaughlin M.E., Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000, 26:109-113.
94. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.